HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference

Stock News

2025/10/02

HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.

The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1155672705"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155672705\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155672705?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155672705","market":"sh","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference","media":"Stock News","content":"<p>HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.</p>\n<p>The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Clinical Data at 2025 European Society for Medical Oncology (ESMO) Annual Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-02 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.</p>\n<p>The registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4531","symbol_name":"中概回港概念","start_time":0,"source_url":"","article_id":"1155672705","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155672705","pubTimestamp":1759363822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4531":"中概回港概念","BK1588":"回港中概股","BK4588":"碎股","BK1191":"制药","BK1587":"次新股","BK4585":"ETF&股票定投概念","00013":"和黄医药","BK4007":"制药","HCM":"和黄医药"},"translate_title":"和黄医药(00013)将在2025年欧洲肿瘤内科学会(ESMO)年会上展示临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced that the company will present the latest and updated data from multiple studies of its proprietary compounds at the European Society for Medical Oncology 2025 Annual Conference, scheduled to take place from October 17-21, 2025, in Berlin, Germany.\nThe registrational FRUSICA-2 study results evaluating fruquintinib in combination with sintilimab as second-line therapy for locally advanced or metastatic renal cell carcinoma will be presented during the mini oral presentation session. Additionally, further analytical results from the FRUSICA-1 study investigating fruquintinib for endometrial cancer treatment, as well as the SACHI and SAVANNAH studies examining savolitinib for non-small cell lung cancer treatment, will be showcased in the poster presentation sessions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}